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Abstract
Background: We have recently shown that serum relaxin-2 levels are attenuated in women with a history of recurrent 
pregnancy loss (RPL). We sought to determine whether a history of RPL is also associated with changes in serum matrix 
metalloproteases (MMPs) and tissue inhibitors of matrix metalloproteases (TIMP) -1 and -2.
Methods: We obtained serum from 20 pregnant women with a history of RPL and 20 age-matched pregnant women 
with no history of RPL (NRPL) at 6-8, 10-12, 20, and 34 weeks gestation, and from cord blood. We quantified total serum 
concentrations of MMP-1, MMP-3, MMP-9 and TIMP-1 and TIMP-2 by ELISA. We determined whether these serum 
marker levels were associated with a history of RPL and delivery before 37 weeks gestation.
Results: There was no difference in the rates of miscarriage, preterm birth or prelabour rupture of fetal membranes 
between RPL and NRPL. However babies born to RPL were lighter than those born to NRPL. Serum MMP-1, 9, and TIMP-
1 did not differ between RPL and NRPL but MMP-3 was higher in RPL vs. NRPL at 6-8 weeks (P < 0.05). Serum TIMP-2 
levels were higher in RPL women at all gestations (P < 0.01). The ratio of RLX-2 (reported previously) to TIMP-2 at 10-12 
weeks gestation was more strongly associated with a history of RPL than either peptide separately - area under the 
ROC curves for RLX-2 0.79 (95% CI 0.57 to 0.92), TIMP-2 0.83 (95% CI 0.63 to 0.95), and for RLX-2:TIMP-2 ratio 0.92 (95% CI 
0.74 to 0.99).
Conclusions: Women with a history of RPL demonstrate increased serum TIMP-2 and reduced RLX-2 during a 
subsequent viable pregnancy. Determination of both markers in early pregnancy enhances the discrimination of 
women with a history of RPL. These observations suggest roles for these two peptides in early implantation and 
placental development. Whether these may prove to be reliable early predictive markers for subsequent pregnancy 
loss in the index pregnancy is unknown and will require further studies.
Background
Recurrent pregnancy loss (RPL) is a distressing clinical
problem and affects 1% of all women. Although some of
the associated conditions are known [1-4], the aetiology
remains poorly understood and the course of any future
pregnancy remains uncertain. Several serum factors are
altered in some women with RPL but none of them reli-
ably predicts repeat miscarriage [5-8]. Insulin resistance
characterises RPL associated with the polycystic ovary
(PCOS) syndrome but is not a reliable marker for repeat
pregnancy loss [3].
We have recently demonstrated that serum Relaxin-2
(RLX-2) levels are attenuated in women with a history of
RPL [9] and correlate with uterine artery Doppler resis-
tance parameters in first trimester, consistent with a cru-
cial role for this peptide in implantation and placental
development [10,11]. Higher rates of adverse pregnancy
outcomes associated with uteroplacental insufficiency
have been reported in women with a history of RPL [12].
Matrix metalloproteinases (MMPs) are a family of pro-
teolytic enzymes that play a central role in the breakdown
and reorganization of extracellular matrix. The group
consists of > 20 members and includes collagenases
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Page 2 of 9(MMP-1, -8, and -13), stromelysins (MMP-3, -7, and -10),
and gelatinases (MMP-2 and -9). Tissue inhibitors of
matrix metalloproteinases (TIMPs) metabolise MMPs
and relaxin has been noted to regulate MMP and TIMP
activity in several tissues [13-15]. Together with relaxin
[16], MMPs and TIMPs appear to play some roles in
embryo implantation, trophoblast invasion, early placen-
tation, and cervical dilatation and feto-maternal mem-
brane lysis in later gestation [16,17]. Importantly, the
secretion of MMPs and TIMPs by trophoblast cells is reg-
ulated by the composition of the surrounding extracellu-
lar matrix [18]. Consistent with these roles, we
hypothesized that women with a previous history of RPL
may demonstrate altered expression levels of some
MMPs and TIMPs, similar to our observations for RLX.
We compared the serum concentrations of interstitial
collagenase (MMP-1), stromelysin-1 (MMP-3), gelatinase
B (MMP-9), TIMP-1 and TIMP-2 in aliquots of serum
stored from women with a history of RPL and age-
matched pregnant controls without a previous history of
miscarriage at several gestational time points.
Methods
Subjects
Frozen aliquots of serum obtained from 20 pregnant
women with a history of RPL (defined as the loss of three
or more consecutive pregnancies before 24 weeks) and 20
age-matched pregnant controls with no previous history
of RPL or an identified association with RPL, stored at -
80°C, were assayed for MMP-1, -3, -9, and TIMP-1 and -
2. Serum samples had been obtained and aliquoted at 6-8,
10-12, 20, and 34 weeks gestation during a previous study
[9]. We excluded women who smoked cigarettes from the
study. Sample sizes were determined as previously
described [9]. We estimated that the 20 subjects in each
study arm would detect a 10% difference in MMP and
TIMP levels between groups with 80% power at the 95%
confidence level. Written informed consent was obtained
from each study participant. Ethical permission was
obtained from the South Sheffield Research Ethics com-
mittee.
Study design
The protocol and time points for serum sample collection
and preparation were as previously reported [9]. At ≥ 10
wks, fetal biometry and uterine artery Doppler indices
were simultaneously measured by transabdominal ultra-
sound [16].
Laboratory analysis
Serum MMP-1, -3, and -9 and serum TIMP-1 and -2 total
concentrations (free and protein bound fractions) were
measured using enzyme immunoassay kits (Catalog
Numbers QIA55, QIA56, QIA73, QIA54, QIA40 respec-
tively, Callbiochem, San Diego, USA) according to the
manufacturer's instructions. The assays were based on
the quantitative sandwich enzyme technique. Test sam-
ples and standards were pipetted onto the surface of the
plastic wells containing monoclonal antibodies specific
for the respective MMP or TIMP provided in the kit. The
specific human protein present thus got bound to the
capture antibody. Unbound material was then washed
away and a monoclonal, horseradish peroxidase (HRP)-
conjugated specific anti-MMP or anti-TIMP antibody
was added to the wells, followed by a chromogenic sub-
strate. The horseradish peroxidase catalysed the conver-
sion of a chromogenic substrate from a colorless solution
to a blue solution, the intensity of which was proportional
to the amount of human MMP or TIMP protein in the
test sample. The coloured reaction product was then
quantified using a spectrophotometer by the construc-
tion of a standard curve using known concentrations of
the respective human MMP or TIMP protein (provided
lyophilized) as internal controls. All the kits for all the
analytes were highly precise, with inter- and intra-assay
coefficients of variation < 10%.
Doppler studies
The rationale for, and assessment of, maternal uterine
artery (UA) Doppler velocimetry have been described
previously [9,19]. The resistance index (RI) has been
shown to be the most repeatable and least variable of the
UA Doppler indices. We therefore employed the average
RI of the left and right UA Doppler waveform for tests of
association. All clinical details, including the pregnancy
outcome for both groups, were recorded.
Outcome measures
We determined whether MMP and or TIMP levels a) bet-
ter separated women with a history of RPL from those
without; b) demonstrated any correlation with serum
RLX-2 or UA RI indices and c) were associated with
spontaneous miscarriage, delivery < 37 weeks, small for
gestational age (birth weight < 10th customized centile
for gestation [20]), placental abruption or stillbirth.
Data analysis
Serum MMP and TIMP levels were compared by one-
way ANOVA, the student t-test (for normally distributed
data) or the Mann-Whitney U test (for data not normally
distributed) with appropriate post hoc correction (the
Bonferroni test) for repeated measures and multiple com-
parisons. Binary logistic regression analyses and the area
under the Receiver Operator Characteristic (AuROC)
curves were used to test association between MMP and
TIMP levels and categorical clinical outcome variables.
Where data regarding serum markers were missing a list-
wise deletion approach was adopted for analysis.
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The clinical details of study participants and the outcome
of their pregnancies have been published previously [9],
and only details pertinent to this report are summarized
in Table 1. Of the 20 participants with a history of RPL,
12(60%) had idiopathic RPL, 5(25%) had the APS, and
3(15%) had the PCOS associated with suspected luteal
phase deficiency. All those with the APS received low
molecular weight heparin (LMWH) and low-dose (75
mg) aspirin throughout pregnancy. There were no still-
births in either group and only one miscarriage in the
RPL group. There was no significant difference in mater-
nal body mass index, pregnancy duration, rates of pre-
term birth and prelabour rupture of fetal membranes
between study groups and between aetiological associa-
tion subtypes in women with RPL.
Serum MMP-1, -3, -9 and TIMP-1 and -2 levels in our
study groups did not differ with maternal gravidity or
parity (Table 1). MMP-1, MMP-9, and TIMP-1 did not
differ between RPL and NRPL groups at all study gesta-
tions, and between aetiological association subtypes in
the women with RPL. Serum levels of MMP-3 were
higher in RPL compared to NRPL at 6-8 weeks gestation
(P < 0.05) but did not differ at other gestational time
points. In contrast, TIMP-2 levels were significantly
higher in women with a history of RPL compared to
NRPL at all gestational time points (Table 1, Figure 1),
whilst umbilical cord serum levels of all study proteins
did not differ. Furthermore, expressing serum RLX-2
(reported in an earlier assay [9] and TIMP-2 levels as a
ratio improved the strong individual associations with a
history of RPL, increasing the AuROC curves at all study
gestations (Table 2). Comparison of AuROC curves
showed that the stronger association of low RLX-
2:TIMP-2 ratios with a history of RPL attained statistical
significance at 10-12 weeks gestation, compared to RLX-2
levels alone (P < 0.05, Figure 2).
At 10-12 wks gestation a RLX-2:TIMP-2 ratio ≤ 0.1 was
best associated with a history of RPL [sensitivity 100%,
specificity 75%, LR+ 4.0 95% CI 2.9 - 5.5, LR- 0.00 95% C1
0.01 - 0.9, P < 0.0001), Table 2]. At 20 wks gestation RLX-
2:TIMP-2 ratio ≤ 0.05 was best associated with a history
of RPL [sensitivity 67%, specificity 80%, LR+ 3.3 95% CI
2.1 - 5.4, LR- 0.42 95% C1 0.1 - 1.5, P < 0.001), Table 2]
Among women with RPL serum MMP and TIMP levels
did not differ by cause of miscarriage or by treatment
with aspirin or LMWH (data not shown).
Stepwise logistic regression analysis (factors included
in the model: maternal age and body mass index, RLX-
2:TIMP2 ratios at study gestations) demonstrated that
the RLX-2:TIMP-2 ratios in RPL were lower than in
NRPL group at 10-12 wks gestation (regression coeffi-
cient -0.43, SE 0.2, OR 0.65, 95% CI 0.44, 0.97, P <
0.0001), at 20 wks gestation (regression coefficient -2.0,
SE 0.1, OR 0.80, 95% CI 0.65, 0.98, P < 0.01), and at 34
wks gestation (regression coefficient -0.36, SE 0.2, OR
0.70, 95% CI 0.49 to 0.99, P < 0.01).
MMP-1, -3, -9, and TIMP-1 and -2 levels did not corre-
late with the average UA RI at any gestation. At all study
gestations serum levels of MMPs and TIMPs were not
significantly different in women who had prelabour rup-
ture of membranes < 1 hour compared to women who
went into labour with intact membranes. Furthermore,
levels did not correlate with fetal birth weight and pre-
term delivery with one exception: the mean (SE) concen-
trations of MMP-3 at 20 weeks gestation were higher in
women who delivered before 37 weeks gestation (8.8 ±
0.7 ng/ml) than those who delivered at term (4.7 ± 0.4 ng/
ml, P < 0.01). Without regard to history of previous preg-
nancy loss, serum MMP-3 at 20 weeks gestation appeared
predictive of delivery before 37 completed weeks (n = 5)
with an AuROC of 0.91 (95% CI 0.76, 0.98, P < 0.001):
serum MMP-3 > 6 ng/ml appeared to predict delivery
before 37 weeks with a sensitivity of 100%, a specificity of
81%, and a +ve likelihood ratio of 5.2 (95% CI 4.3, 6.1),
Figure 3.
Levels of studied proteins in cord blood did not differ
between RPL and NRPL, and did not correlate with their
antenatal levels, Doppler indices, fetal birth weight, ges-
tational age at delivery or prelabour amniorrhexis.
Discussion
We report, for the first time, that during a viable preg-
nancy, women with a history of RPL have raised serum
levels of TIMP-2 whilst MMP-1, -3, and -9 are not signifi-
cantly altered. We have also previously reported reduced
serum RLX levels in these women, and our current obser-
vations suggest that both serum RLX and TIMP-2 con-
centrations discriminate between pregnant women with a
history of RPL and those without. Expressed as a ratio,
RLX-2:TIMP-2 < 0.1 at 10-12 weeks gestation was
strongly associated with a history of RPL, achieving a
sensitivity of nearly 100%, a specificity of 75% and a posi-
tive likelihood ratio of 4. Our observations suggest func-
tional roles for these two peptides during early pregnancy
development. However, our limited sample sizes pre-
cluded determination of any predictive relationship
between these peptides and pregnancy loss, and adverse
outcome in the index pregnancy, highlighting the need
for larger scale prospective studies.
We have compared two groups of pregnant women that
were matched for age and differed only with respect to
their previous history of recurrent pregnancy loss. Con-
sequently, differences in the serum concentrations of the
study peptides between the two groups are likely to be
attributable to their status with respect to a history of
RPL. A raised TIMP-2 level in pregnant women with a
history of RPL suggests that TIMP-2 plays a role in early
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Table 1: Subject characteristics, pregnancy outcome, and serum levels of MMPs and TIMPs, pregnant women with a 
history of RPL vs. pregnant women with no history of RPL
History of recurrent 
pregnancy loss, RPL
No history of recurrent 
pregnancy loss, NRPL
P value
n 20 20
Median (range) age (yrs) 32.5 (20 - 43) 31.0 (24-41) 0.8
Mean (SE) birth weight (g) 3040 (206) 3364 (216) 0.15
Infant birth weight < 2500 g, n (%) 7 (35) 3 (15) 0.15
Small for gestational age (birth weight < 10th centile) 5 (25%) 0 0.048
Mean (SE) serum MMP-1 levels in ng/ml
6-8 wks 346 (36) 438 (104) 0.35
10-12 wks 355 (52) 366 (55) 0.69
20 wks 337 (29) 380 (71) 0.55
34 wks 524 (52) 529 (104) 0.97
Cord serum 375 (41) 476 (115) 0.36
Mean (SE) serum MMP-3 levels in ng/ml
6-8 wks 5.6 (0.7) 3.2 (0.4) 0.01
10-12 wks 7.4 (2.4) 5.2 (0.7) 0.39
20 wks 5.3 (0.7) 5 (0.7) 0.74
34 wks 4.7 (0.6) 5 (0.6) 0.64
Cord serum 1.8 (0.4) 1.8 (0.4) 0.90
Mean (SE) serum MMP-9 levels in ng/ml
6-8 wks 70.0 (6.9) 86.0 (15.3) 0.31
10-12 wks 91.5 (10.3) 83.3 (13.0 0.62
20 wks 105.8 (12.4) 80.6 (12.8) 0.15
34 wks 89.4 (11.3) 111.8 (14.6) 0.23
Cord serum 47.6 (8.7) 51.7 (7.4) 0.72
Mean (SE) serum TIMP-1 levels in ng/ml)
6-8 wks 20.0 (2.0) 17. 1 (2.4) 0.37
10-12 wks 23.7 (1.8) 20.6 (3.5) 0.42
20 wks 23.9 (2.8) 23.3 (2.7) 0.88
34 wks 18.4 (2.1) 18.9 (2.4) 0.87
Cord serum 17.9 (2.7) 21.7 (3.0) 0.35
Mean (SE) serum TIMP-2 levels in ng/ml
6-8 wks 36.0 (8.4) 13.8 (1.4) 0.01
10-12 wks 31.0(5.2) 11.7 (1.1) 0.002
20 wks 23.6 (5.2) 9.9 (0.9) 0.008
34 wks 23.7 (3.2) 16.9 (1.3) 0.05
Cord serum 16.7 (6.1 11.1 (1.1) 0.44
Relaxin:TIMP-2 ratio*
6-8 wks 0.05 (0.01) 0.18 (0.03) 0.006
10-12 wks 0.05 (0.01) 0.17 (0.03) 0.0001
20 wks 0.03 (0.01) 0.08 (0.02) 0.03
34 wks 0.04 (0.01) 0.13 (0.02) 0.02
Cord serum 0.01 (0.01) 0.00 (0.00) 0.13
* Relaxin levels were derived from an earlier assay [9].
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with some dysregulation of TIMP-2. It is plausible that a
critical level of increased TIMP-2 activity is required
before a pregnancy fails, and that such critical level was
not attained in the women with a history of RPL who
achieved favourable outcomes during the index pregnan-
cies. On the other hand, the observed rise in TIMP-2 lev-
els in the RPL group may serve to sustain the at-risk
pregnancy. Further studies are required to elucidate the
physiological roles of TIMP-2 and relaxin during early
pregnancy, and to determine whether the altered expres-
sion levels of TIMP-2 and relaxin-1 during pregnancy to
women with a history of RPL contribute to the cause or
are a consequence of recurrent pregnancy loss.
The levels of MMP-1 -3, and -9 are unaltered in RPL in
comparison to NRPL. Serum TIMP-1 concentrations also
did not differ with history of RPL, consistent with the
thesis that TIMP-1 and TIMP-2 have distinct individual,
perhaps tissue-specific, as yet ill-understood, biological
functions.
Although originally characterized as inhibitors of MMP
activity, TIMPs are known to have distinct MMP-inde-
pendent functions in biological tissues, being involved in
cell growth, migration and apoptosis [21,22]. TIMP-1 has
adipokinetic effects [19] while TIMP-2 is a potent inhibi-
tor of angiogenesis [23]. Recent studies have identified
specific signaling pathways and cell surface binding part-
ners for members of the TIMP family. TIMP-2 binding to
the integrin α3β1 is the first description of a cell surface
receptor for a TIMP family member [24,25]. TIMP-2 has
also been shown to induce gene expression, promote G1
cell cycle arrest, and inhibit cell migration whilst TIMP-1
binding to CD63 inhibits cell growth and apoptosis [21].
These findings suggest that TIMPs play complex roles in
controlling cell fate, acting directly through cell surface
receptors and indirectly through modulation of protease
activity [21].
TIMP-2 levels are elevated in the third trimester in
women with impaired glucose tolerance and gestational
diabetes [26]. Although reports are conflicting, some
women with RPL (particularly those with PCOS) demon-
strate insulin resistance [3,27-29]. Insulin resistance may
therefore partly explain our observation of raised TIMP-2
levels in those women with a history of RPL. Stojanovic et
Figure 1 Serum concentrations of matrix proteins and their inhibitors in study groups. Comparison of serum concentrations (ng/ml) of 
MMP-1, MMP-3, MMP-9, TIMP-1, TIMP-2, and ratio of RLX to TIMP-2, RPL vs NRPL, * P < 0.05, ** P < 0.01.
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MMP-2, was strongly correlated with impaired glucose
tolerance. Furthermore, a murine model of hyperinsuli-
naemia and insulin resistance is associated with increased
TIMP-1 and -2 levels, suggesting that insulin homeostasis
may affect extracellular matrix metabolism via TIMP-
mediated processes [30].
Our observation of elevated TIMP-2 levels in women
with a history of RPL may suggest that functional dysreg-
ulation of this protein may contribute to early pregnancy
failure by altering matrix remodeling at the implantation
site (through regulation of proteinases) and inhibiting
angiogenesis (through a direct effect at the choriodecid-
ual interface). TIMP-2 inhibits fibroblast growth factor-
stimulated proliferation of human endothelial cells via a
MMP-independent signaling mechanism [31], consistent
with this thesis. Control of cellular growth and differenti-
ation by TIMPs via MMP-dependent regulation of insulin
growth-factor binding protein availability has also been
described [32].
To our knowledge, this is the first report of serum levels
of representative MMPs and TIMPs during human preg-
nancy. MMP-2 and -9 serum levels are reported to be
increased in women with pre-eclampsia [33-35]. Pro-
MMP-9 levels increase whilst TIMP-1 levels decrease
prior to labour [36], and following preterm amniorrhexis
[37]. We could not confirm the latter observation in our
cohort of women who had prelabour membrane rupture
> 1 hour as our data sets were small and our last maternal
serum samples were taken remote from term (at 34 weeks
gestation).
An important caveat to our observations is that we have
studied systemic rather than gravid tissue MMP and
TIMP levels. We may therefore have missed more pro-
found local changes associated with early pregnancy
development or prelabour fetal membrane rupture in late
pregnancy. Nonetheless, we still demonstrated dramatic
differences in serum relaxin and TIMP-2 concentrations,
suggesting that further studies may provide additional
mechanistic insight into the biology of these molecules in
human reproduction. The limitations of extrapolating
serum levels of these molecules to their function in local
reproductive tissue notwithstanding, it is still plausible
that they may prove of predictive clinical value for
adverse pregnancy outcomes such as miscarriage. Mea-
suring serum levels of these proteases and their inhibitors
are currently being investigated as preclinical and clinical
markers of disease progression in advanced cancers of
various organ systems [38].
Despite our limited sample sizes, we observed, for the
first time, a strong association between high MMP-3 lev-
els and delivery before 37 weeks gestation. This observa-
tion is in keeping with reports of increased levels of
MMP-3 in the amniotic fluid and maternal decidua of
women with chorioamnionitis and inflammation-
induced preterm delivery [39,40]. Larger studies are
required to confirm whether MMP-3 levels are elevated
by 20 weeks gestation in women who deliver before 37
weeks as this intriguing observation could prove a useful
adjunct to current screening tools for preterm delivery.
Our experimental model has several draw-backs and
limitations. Firstly, several different tissues contribute to
systemic levels of serum markers and local expression
levels are likely to vary by tissue. The contribution of
reproductive tract tissue to serum levels of MMPs and
TIMPs during pregnancy is unknown and inferences
regarding activity of these serum markers in gravid repro-
ductive tract tissues may be somewhat spurious. How-
ever, we have compared age-matched cohorts of pregnant
women with and without a history of RPL and our
observed differences are therefore highly likely to reflect
the underlying differences in their history of recurrent
pregnancy loss. Secondly, our sample sizes were small
and our study may have been under-powered to detect
weaker associations of serum marker levels and the clini-
cal outcome measures investigated. Larger scale prospec-
tive studies of cohorts with sufficient subpopulations of
women with adverse pregnancy outcomes will be
required to confirm or refute any potential predictive
clinical utility of assessing serum relaxin and TIMP-2 lev-
els. The miscarriage rates in the index pregnancy in our
series were so low that we could not determine the tem-
Figure 2 Association of relaxin and TIMP-2 with a history of RPL. 
ROC curves comparing association of RLX-2, TIMP-2 and RLX-
2:TIMP-2 ratios at 10-12 weeks gestation in women with a history 
of RPL (*vs. RLX-2:TIMP-2, P < 0.05).
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Table 2: Area under the ROC curves (AuROC) and associations between serum Relaxin, TIMP-2 and relaxin:TIMP-2 ratios and a history of RPL
AuROC (95% CI) P value Optimal predictive
 cut-off value
Sensitivity (95% CI) Specificity (95% CI) +LR (95% CI) -LR (95% CI)
6-8 wks gestation
Relaxin (ng/ml) 0.65 (0.50 - 0.80) < 0.05 < = 1.3 80.00 (56.3 - 94.3) 46.67 (21.3 - 73.4) 1.50 (0.8 - 2.7) 0.43 (0.2 - 1.2)
TIMP-2 (ng/ml) 0.84 (0.60 - 0.97) < 0.001 > 14 77.78 (40.0 - 97.2) 70.00 (34.8 - 93.3) 2.59 (1.5 - 4.4) 0.32 (0.07 - 1.5)
Relaxin:TIMP-2 ratio 0.89 (0.67-0.99) < 0.0001 <= 0.06 77.78 (40.0 - 97.2) 90.00 (55.5 - 99.7) 7.78 (5.2 - 11.7) 0.25 (0.03 - 2.3)
10-12 wks gestation
Relaxin (ng/ml) 0.73 (0.54 - 0.90) < 0.05 <= 1.7 95.00 (75.1 - 99.9) 42.11 (20.3 - 66.5) 1.64 (1.0 - 2.8) 0.12 (0.02 - 0.8)
TIMP-2 (ng/ml) 0.83 (0.63 - 0.95) < 0.001 > 10 75.00 (42.8 - 94.5) 83.33 (51.6 - 97.9) 4.50 (3.0 - 6.8) 0.30 (0.06 - 1.5)
Relaxin:TIMP-2 ratio 0.92 (0.74 - 0.99) < 0.0001 <= 0.09 100.00 (73.5 - 100.0) 75.00 (42.8 - 94.5) 4.00 (2.9 - 5.5) 0.00 (0.01 - 0.9)
20 weeks gestation
Relaxin (ng/ml) 0.77 (0.58 - 0.90) < 0.01 <= 0.71 78.95 (54.4 - 93.9) 61.11 (35.7 - 82.7) 2.03 (1.3 - 3.1) 0.34 (0.1 - 1.0)
TIMP-2 (ng/ml) 0.73 (0.52 - 0.88) < 0.05 > 20 50.00 (21.1 - 78.9) 100.00 (78.2 - 100.0) 0.50
Relaxin:TIMP-2 ratio 0.81(0.61-0.93) < 0.001 <= 0.05 66.67 (34.9 - 90.1) 80.00 (51.9 - 95.7) 3.33 (2.1 - 5.4) 0.42 (0.1 - 1.5)
34 weeks gestation
Relaxin (ng/ml) 0.68 (0.48 - 0.84) 0.13 <= 0.9 94.44 (72.7 - 99.9) 47.06 (23.0 - 72.2) 1.78 (1.1 - 3.0) 0.12 (0.02 - 0.8)
TIMP-2 (ng/ml) 0.67 (0.46 - 0.85) 0.11 >14 66.67 (34.9 - 90.1) 30.77 (9.1 - 61.4) 0.96 (0.4 - 2.4) 1.08 (0.5 - 2.6)
Relaxin:TIMP-2 ratio 0.77 (0.56- 0.92) <0.01 <= 0.04 83.33 (51.6 - 97.9) 76.92 (46.2 - 95.0) 3.61 (2.4 - 5.3) 0.22 (0.04 - 1.1)
Umbilical cord levels
Relaxin (ng/ml) 0.52(0.32 - 0.71) NS
TIMP-2 (ng/ml) 0.50 (0.28 - 0.72) NS
Relaxin:TIMP-2 ratio 0.56 (0.32-0.78) NS
NS: not significant.
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Page 8 of 9poral relationship, if any, between serum RLX-2 and
TIMP-2 levels and subsequent miscarriage. This determi-
nation is the subject of ongoing studies.
Low serum relaxin appears to enhance the strong asso-
ciation of high TIMP-2 levels with a history of RPL, sug-
gesting that these two peptides may regulate endometrial
or placental angiogenesis through synergistic mecha-
nisms, either directly or via the inhibition of angiogenic
growth factors such as vascular endothelial growth factor
(VEGF) and placental growth factor [41,42].
Conclusions
We have demonstrated that serum TIMP-2 levels are
increased during pregnancy to women with a history of
RPL in comparison to pregnant controls with no history
of RPL. Furthermore, when expressed as a ratio of serum
relaxin, there is an enhanced separation at 10-12 weeks
gestation, of women with a history of RPL from those
without. We have also noted, despite a limited sample
size, that raised serum MMP-3 levels at 20 weeks gesta-
tion appears predictive of delivery before 37 weeks. Taken
together, our data suggest that dysregulated RLX-2 and
TIMP-2 may play a role in habitual early pregnancy fail-
ure. Further prospective studies of larger cohorts are
required to confirm or refute these observations, and to
investigate any predictive clinical utility.
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